EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

Gillian Murphy, Hideaki Nagase

Nature Clinical Practice Rheumatology · 2008-03 · 4 (3) · 128-135

DOI: 10.1038/ncprheum0727 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Clinical Practice Rheumatology, online erschienen am 05.02.2008. Verfasst von Gillian Murphy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Cell Biology, Department of Oncology, University of Cambridge, Cambridge, UK. Die Arbeit wurde bisher 270-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metalloproteinases such as the matrix metalloproteinases (MMPs) and disintegrin-metalloproteinases with thrombospondin motifs (ADAMTSs) have been implicated in the pathological destruction of joint tissues in rheumatoid arthritis and osteoarthritis. These enzymes degrade extracellular matrix macromolecules and modulate factors governing cell behavior. They may also be involved in tissue repair, but become a part of the destructive disease process due to overexpression. Studies investigating the roles of metalloproteinases have thrown light on the failure of the early clinical trials of MMP inhibitors as therapeutic agents in arthritic diseases. It is now clear that a more accurate knowledge of the enzymes in the different cells and their precise roles in the disease process is required for these approaches to be successful. The next generations of metalloproteinase inhibitors should have added specificity, gained from an understanding not only of the catalytic domain structures but the role of extracatalytic motifs in substrate binding, or by the generation of engineered tissue inhibitors of metalloproteinases. Inhibition of the enzymes by modulating gene expression or preventing protein activation could also be considered. Work on the development of effective biomarkers is also essential before an effective evaluation of the new generations of specific inhibitors can be made.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBiomarkersCartilageEnzyme InhibitorsHumansJointsMetalloproteasesOsteoarthritisTissue Inhibitor of Metalloproteinases

Substanzen

BiomarkersEnzyme InhibitorsTissue Inhibitor of MetalloproteinasesMetalloproteases

Autor:innen und Institutionen

  • Cancer Cell Biology, Department of Oncology, University of Cambridge, Cambridge, UK.

Förderung

  • Wellcome Trust

Zitieren

APA

Murphy, G., & Nagase, H. (2008). Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?. Nature Clinical Practice Rheumatology, 4(3), 128-135. https://doi.org/10.1038/ncprheum0727

Vancouver

Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?. Nature Clinical Practice Rheumatology. 2008;4(3):128-135. doi:10.1038/ncprheum0727

BibTeX
@article{Murphy2008,
  author = {Murphy, Gillian and Nagase, Hideaki},
  title = {Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?},
  journal = {Nature Clinical Practice Rheumatology},
  year = {2008},
  volume = {4},
  number = {3},
  pages = {128--135},
  doi = {10.1038/ncprheum0727}
}
Kostenlos starten →